Nemaura Medical PLC is a medical technology company focused on developing non‐invasive monitoring solutions for diabetes management and other metabolic applications. The company’s core offering centers on sugarBEAT, a wearable continuous glucose monitoring (CGM) system designed to provide real-time glucose readings through a disposable skin patch. By eliminating the need for finger-stick testing, Nemaura aims to improve patient comfort and adherence, particularly for individuals managing type 1 and type 2 diabetes.
The sugarBEAT system utilizes a proprietary, mild electric current to extract interstitial fluid through micro-pores in the skin, enabling glucose measurement without needle penetration. Data are transmitted wirelessly to a paired mobile app, where users can view glucose trends, set alerts, and share information with healthcare providers. In addition to glucose monitoring, Nemaura is investigating the extension of its platform to measure other biomarkers, such as lactate and alcohol levels, broadening the potential applications of its non-invasive sensor technology.
Nemaura Medical secured CE mark approval for sugarBEAT in Europe and has initiated commercial rollouts in select markets, aiming to expand distribution through partnerships with diabetes care providers and pharmacies. The company is pursuing additional regulatory clearances, including U.S. Food and Drug Administration (FDA) approval, to enter the North American market. As part of its global strategy, Nemaura continues to engage with clinical research organizations and diabetes advocacy groups to demonstrate the clinical and economic benefits of its non-invasive monitoring approach.
Founded in the United Kingdom and headquartered in Leamington Spa, Nemaura Medical went public on the Nasdaq under the ticker NMRD in 2019. The company is led by founder and CEO Dr. Faz Chowdhury, whose background in medical engineering and diabetes research guides Nemaura’s innovation roadmap. With a growing commercial footprint and ongoing product development initiatives, Nemaura seeks to transform chronic disease management through patient-friendly, non-invasive technologies.
AI Generated. May Contain Errors.
Free NMRD Stock Alerts